7,701 Shares in Natera, Inc. $NTRA Acquired by Focus Partners Advisor Solutions LLC

Focus Partners Advisor Solutions LLC purchased a new position in shares of Natera, Inc. (NASDAQ:NTRA) in the second quarter, Holdings Channel reports. The fund purchased 7,701 shares of the medical research company’s stock, valued at approximately $2,090,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Integrated Wealth Concepts LLC boosted its holdings in shares of Natera by 6.6% in the 1st quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company’s stock valued at $221,000 after acquiring an additional 96 shares during the last quarter. NewEdge Advisors LLC raised its holdings in shares of Natera by 68.3% during the first quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company’s stock worth $644,000 after purchasing an additional 1,847 shares during the last quarter. Focus Partners Wealth raised its holdings in shares of Natera by 8.6% during the first quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company’s stock worth $847,000 after purchasing an additional 474 shares during the last quarter. Sivia Capital Partners LLC acquired a new position in Natera during the second quarter valued at $298,000. Finally, WINTON GROUP Ltd acquired a new position in Natera during the second quarter valued at $558,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Natera Stock Performance

Shares of NASDAQ NTRA opened at $309.93 on Friday. The company has a market capitalization of $44.67 billion, a PE ratio of -227.89 and a beta of 1.51. The company’s fifty day moving average price is $263.76 and its 200 day moving average price is $226.40. Natera, Inc. has a 1 year low of $156.71 and a 1 year high of $326.03.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.02. The company had revenue of $752.75 million during the quarter, compared to analysts’ expectations of $661.24 million. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The firm’s revenue for the quarter was up 37.7% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.74) earnings per share. On average, equities analysts expect that Natera, Inc. will post -1.11 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Royal Bank Of Canada upped their price target on shares of Natera from $275.00 to $350.00 and gave the company an “outperform” rating in a report on Friday, August 7th. Wolfe Research began coverage on Natera in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $260.00 price objective for the company. Canaccord Genuity Group set a $375.00 price objective on Natera in a report on Friday, August 7th. Stephens upped their target price on Natera from $305.00 to $350.00 and gave the stock an “overweight” rating in a research note on Wednesday. Finally, Wall Street Zen lowered Natera from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $319.38.

Insiders Place Their Bets

In related news, CEO Steven Leonard Chapman sold 3,076 shares of the company’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $266.39, for a total value of $819,415.64. Following the completion of the transaction, the chief executive officer owned 99,897 shares of the company’s stock, valued at approximately $26,611,561.83. This represents a 2.99% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Michael Burkes Brophy sold 478 shares of the stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $274.22, for a total value of $131,077.16. Following the transaction, the chief financial officer owned 51,637 shares in the company, valued at $14,159,898.14. This represents a 0.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 181,045 shares of company stock valued at $41,330,968 over the last quarter. Insiders own 5.05% of the company’s stock.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.